US 12,240,920 B2
Cyclic peptidomimetic for the treatment of neurological disorders
John Marshall, Barrington, RI (US)
Assigned to BROWN UNIVERSITY, Providence, RI (US)
Filed by Brown University, Providence, RI (US)
Filed on Dec. 6, 2023, as Appl. No. 18/531,607.
Application 18/531,607 is a continuation of application No. 17/690,809, filed on Mar. 9, 2022, granted, now 11,879,020.
Application 17/690,809 is a continuation of application No. 17/036,059, filed on Sep. 29, 2020, abandoned.
Claims priority of provisional application 62/909,396, filed on Oct. 2, 2019.
Prior Publication US 2024/0182524 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/52 (2006.01); A61P 9/10 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01)
CPC C07K 7/52 (2013.01) [A61P 9/10 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01)] 6 Claims
 
1. A composition comprising a therapeutically effective amount of dR7-2097 or a pharmaceutically acceptable salt thereof, wherein the dR7-2097 comprises RRRRRRRC (SEQ ID NO: 2 or PolyArg) in the following dR7-2097 structure:

OG Complex Work Unit Chemistry
wherein the PolyArg consists of all the R enantiomer, (R)-Arg or (“R”)-arginine, and all the S enantiomer, (“S”)-cysteine amino acids in the RRRRRRRC (SEQ ID NO: 2); and
wherein in the dR7-2097 there is a disulfide linkage from the(S)-Cys or (“S”)-cysteine to one (R)-Cys or (“R”)-cysteine.